These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2449084)

  • 1. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
    Kawai T; Greenberg SD; Truong LD; Mattioli CA; Klima M; Titus JL
    Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of blood group-related antigens and Helix pomatia agglutinin in malignant pleural mesothelioma and pulmonary adenocarcinoma.
    Kawai T; Suzuki M; Torikata C; Suzuki Y
    Hum Pathol; 1991 Feb; 22(2):118-24. PubMed ID: 2001875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lectin histochemistry of normal lung and pulmonary adenocarcinoma.
    Kawai T; Greenberg SD; Titus JL
    Mod Pathol; 1988 Nov; 1(6):485-92. PubMed ID: 3222257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
    Sheibani K; Battifora H; Burke JS
    Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.
    Corson JM; Pinkus GS
    Am J Pathol; 1982 Jul; 108(1):80-8. PubMed ID: 6178295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
    Oates J; Edwards C
    Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
    Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J
    Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry in the diagnosis of malignant mesothelioma.
    Pfaltz M; Odermatt B; Christen B; Rüttner JR
    Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
    Han AC; Peralta-Soler A; Knudsen KA; Wheelock MJ; Johnson KR; Salazar H
    Hum Pathol; 1997 Jun; 28(6):641-5. PubMed ID: 9190996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
    al-Saffar N; Hasleton PS
    Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.
    Epstein JI; Budin RE
    Hum Pathol; 1986 May; 17(5):514-9. PubMed ID: 2422109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of membranous staining of mesothelioma.
    King JA; Tucker JA
    Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistological study of malignant diffuse mesotheliomas of the pleura.
    Loosli H; Hurlimann J
    Histopathology; 1984 Sep; 8(5):793-803. PubMed ID: 6083969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma.
    Bakir K; Koçer NE; Deniz H; Güldür ME
    Ann Diagn Pathol; 2004 Dec; 8(6):337-41. PubMed ID: 15614737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
    Ordóñez NG
    Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
    Roberts F; Harper CM; Downie I; Burnett RA
    Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma.
    Holden J; Churg A
    Am J Surg Pathol; 1984 Apr; 8(4):277-9. PubMed ID: 6201076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.